Joincare Pharmaceutical Group Industry Co.,Ltd. provided preliminary earnings guidance for the first half of 2018. The company expects net profit belonging to shareholders of the company will increase by between RMB 81,796,300 and RMB 111,861,200 with an increase of between 25.01% and 34.20% compared with the same period of the year before (based on the disclosed statistics according to relevant regulations). The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss will increase by between RMB 84,092,400 and RMB 118,078,100 with an increase of between 29.02% and 40.74% compared with the same period of the year before (based on the disclosed statistics according to relevant regulations).